Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2012 | 02:29pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

James Dodwell

+ 44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
06:43p GLAXOSMITHKLINE : *ubs cuts glaxosmithkline price target to 1600 pence - 'neutra..
05:13p ADAPTIMMUNE THERAPEUTICS : Announces Initiation of Myxoid/Round Cell Liposarcoma..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 Astex Joins the Dementia Discovery Fund as a Strategic Investor
12/05 INNOVIVA : Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 GlaxoSmithKline Says Limet To Step Down As CEO Of ViiV Venture
12/02 INNOVIVA : GSK files EU regulatory submission for once-daily closed triple combi..
12/02 GLAXOSMITHKLINE : NICE recommends first-of-its kind asthma treatment mepolizumab
12/02 GLAXOSMITHKLINE : Files EU Regulatory Submission For COPD Treatment
More news
Sector news : Pharmaceuticals - NEC
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Spark Strengthens Case For Hemophilia Gene Therapy
12/05 GLAXOSMITHKLINE : Robust Pipeline Supports Its 5.5% Dividend Yield
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/02 5%+ DIVIDEND YIELD PORTFOLIO : Trump And The No Good, Very Bad Month (Nov 2016 R..
12/02 Glaxo files marketing application in Europe for inhaled triple combo COPD the..
Advertisement
Financials ( GBP)
Sales 2016 27 380 M
EBIT 2016 7 207 M
Net income 2016 2 601 M
Debt 2016 13 636 M
Yield 2016 5,56%
P/E ratio 2016 30,35
P/E ratio 2017 17,91
EV / Sales 2016 3,10x
EV / Sales 2017 2,87x
Capitalization 71 144 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,9  GBP
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC6.26%90 716
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results